Most Americans have never heard of pharmacy benefit managers, yet PBMs sit at the center of nearly every prescription drug transaction in the country. Three companies — CVS Caremark, Express Scripts, and OptumRx — control roughly 80% of the market. Their business model is structurally opaque, riddled with self-dealing incentives, and difficult to police. Among the many dysfunctional links in US healthcare, PBMs have a strong claim to being the most quietly corrupt.
Rebates create perverse drug-pricing incentives
PBMs negotiate rebates from drug manufacturers in exchange for favorable formulary placement. A higher list price often means a larger rebate, which means more revenue for the PBM, which means the higher-priced drug gets preferred placement. Drugmakers, knowing this, raise list prices to fund the rebates. The patient at the counter pays a copay or coinsurance based on the inflated list price. Senate investigations and academic analyses have documented this dynamic across multiple drug classes, including insulin, where list prices climbed dramatically while net prices to manufacturers stayed roughly flat.
Spread pricing is a quiet markup
In spread pricing arrangements with state Medicaid programs and private plans, PBMs pay pharmacies one amount for a drug, charge the plan a higher amount, and pocket the difference. Multiple state audits — Ohio, Kentucky, and others — have found spreads totaling tens of millions of dollars annually that were not disclosed to the plan sponsor. The PBM’s revenue here is not negotiated value-add. It is concealed margin, extracted from public budgets and private premiums.
Vertical integration removes the checks
The largest PBMs are now owned by, or own, major insurers and pharmacy chains. CVS Health owns Caremark and a major insurer. Cigna owns Express Scripts. UnitedHealth owns OptumRx. The same corporate parent now sets formulary, owns the pharmacy that dispenses the drug, and underwrites the plan that pays for it. Independent pharmacies report being reimbursed below acquisition cost on drugs that the PBM-owned chain across the street is reimbursed favorably for. Antitrust scrutiny is increasing, but enforcement has lagged the consolidation by a decade.
The harm shows up at the counter
Patients experience the dysfunction without seeing the cause. Drugs disappear from formularies, switch tiers without warning, or require step therapy through medications they’ve already failed. Independent pharmacies close at accelerating rates, particularly in rural and lower-income areas, leaving pharmacy deserts. Plan sponsors pay more than they should and have limited tools to audit what they’re being charged. Each of these effects is a downstream consequence of a market structure that is accountable to almost no one.
The takeaway
Reform proposals exist — rebate pass-through requirements, transparency mandates, severing PBM ownership from insurers and pharmacies, banning spread pricing in public programs. They have run into the predictable wall of well-funded lobbying. The political opacity of the PBM business is itself part of the business model: few voters have a target to be angry at. Anyone interested in why American drug prices look the way they do should start with the PBM layer, because most of the dysfunction at the pharmacy counter starts there.
Leave a Reply